Metadata Search Funding Data Link References Status API Help
Facet browsing currently unavailable
Page 1 of 1 results
Sort by: relevance publication year

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer

JOURNAL ARTICLE published November 2009 in Annals of Oncology

Authors: J.M. Del Campo | A. Roszak | M. Bidzinski | T.E. Ciuleanu | T. Hogberg | M.Z. Wojtukiewicz | A. Poveda | K. Boman | A.M. Westermann | C. Lebedinsky